Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 187

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 187
---
 clinical trials, as well as costs associated with safety studies;
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   costs paid to our decentralized manufacturing units (DMUs) where our CAR-T cell therapies are being manufactured, including technology transfer fees, as well as disposables and consumables used in the conduct of our CAR-T clinical trials;
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   professional fees to support our R&amp;D activities;
--------------------------------------------------------

●   consultants and advisory in support of our R&amp;D activities;
------------------------------------------------------------------

●   costs paid to our collaboration partners and reimbursements received from our collaboration partners in the scope of the cost sharing agreements of our collaborations;
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   premises costs associated with our laboratory and office space to accommodate our teams;
--------------------------------------------------------------------------------------------

●   depreciation and impairment of fixed assets used to develop our product candidates; and
-------------------------------------------------------------------------------------------

●   other operating expenses, namely software and licenses, maintenance costs for equipment, travel costs, and office expenses.
-------------------------------------------------------------------------------------------------------------------------------
Our R&D expenses are expected to decrease overall, driven by the announced planned separation with Gilead, the planned reorganization as well as planned discontinuation of our small molecule business , while focusing investments in our cell therapy programs in oncology. Since 2022, we cumulatively have spent €1,290.2 million on R&D activities which can be split as follows between the key programs:

                ​                   ​   ​        ​       ​    ​        ​       ​    ​        ​       ​     ​          ​        ​   ​    ​  
-------------------------------------------------------------------------------------------------------------------------------------------
​                                   ​   Year ended December 31,                                      ​   ​                 ​   ​   ​      ​
​                                   2024                 2023                  2022                      ​                 ​       ​      ​
​                                   ​   ​                                     (Euro, in thousands)   ​   Cumulative            ​   ​      ​
Filgotinib program                  ​   €      (8,152)   ​    €    (190,177)   ​    €    (245,286)   ​   €         (443,615)   ​   ​    34%
Ziritaxestat program                ​   ​            —   ​    ​            —   ​    ​      (1,096)   ​   ​           (1,096)   ​   ​     0%
SIKi program                        ​   ​     (18,400)   ​    ​     (18,900)   ​    ​     (47,